Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 41.9% in October

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,600 shares, a decline of 41.9% from the October 15th total of 6,200 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 12,000 shares, the days-to-cover ratio is currently 0.3 days.

Alterity Therapeutics Trading Down 2.5 %

Shares of ATHE stock opened at $1.16 on Wednesday. Alterity Therapeutics has a 1 year low of $1.01 and a 1 year high of $5.41. The stock has a fifty day moving average of $1.25 and a two-hundred day moving average of $1.58.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.